Skip to main content

Obstructive patterns in videourodynamic studies predict responses of female dysfunctional voiding treated with or without urethral botulinum toxin injection: a long-term follow-up study


Introduction and hypothesis

We report long-term changes in VUDS profiles of women with dysfunctional voiding and investigate potential predictors for treatment response.


Women with dysfunctional voiding and available VUDS data between November 1997 and June 2018 were enrolled for retrospective analysis. The patients were all treated with medication first. In refractory patients, urethral botulinum toxin was provided as an additional option. The primary outcome was the change of VUDS parameters between baseline and follow-up studies. The secondary outcomes were baseline parameters and clinical factors that were associated with the BOOI response (> 10 points of BOOI reduction).


A total of 195 women with DV were included in this study. The mean age was 54.5 years old. Sixty patients received urethral botulinum toxin injection. For all patients, Pdet decreased from 47.2 to 36.8 cm H2O (p < 0.0001), and BOOI decreased from 26.4 to 17.7 (p = 0.0001). Patients with urethral injection had significantly smaller Qmax, voided volume, and voiding efficiency (VE) and significantly larger PVR and BOOI at baseline, indicating a severer obstruction in this group. The overall BOOI response rate was 44% (85/195). A higher baseline BOOI was associated with the BOOI response in multivariate analysis.


In this long-term study of women with dysfunctional voiding, medical treatment with or without urethral botulinum toxin injection both resulted in reduction of Pdet and BOOI. A more prominent obstructive profile at baseline VUDS study was associated with a higher rate of BOOI response at follow-up study.

This is a preview of subscription content, access via your institution.

Fig. 1


  1. Massey JA, Abrams PH. Obstructed voiding in the female. Br J Urol. 1988;61(1):36–9.

    CAS  Article  PubMed  Google Scholar 

  2. Nitti VW, Tu LM, Gitlin J. Diagnosing bladder outlet obstruction in women. J Urol. 1999;161(5):1535–40.

    CAS  Article  Google Scholar 

  3. Groutz A, Blaivas JG, Chaikin DC. Bladder outlet obstruction in women: definition and characteristics. Neurourol Urodyn. 2000;19(3):213–20.

    CAS  Article  Google Scholar 

  4. Choi YS, Kim JC, Lee KS, Seo JT, Kim HJ, Yoo TK, et al. Analysis of female voiding dysfunction: a prospective, multi-center study. Int Urol Nephrol. 2013;45(4):989–94.

    Article  PubMed  Google Scholar 

  5. Meier K, Padmanabhan P. Female bladder outlet obstruction: an update on diagnosis and management. Curr Opin Urol. 2016;26(4):334–41.

    Article  PubMed  Google Scholar 

  6. Kuo HC. Videourodynamic characteristics and lower urinary tract symptoms of female bladder outlet obstruction. Urology. 2005;66(5):1005–9.

    Article  PubMed  Google Scholar 

  7. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn. 2002;21(2):167–78.

    Article  PubMed  Google Scholar 

  8. Gammie A, Kirschner-Hermanns R, Rademakers K. Evaluation of obstructed voiding in the female: how close are we to a definition? Curr Opin Urol. 2015;25(4):292–5.

    Article  PubMed  Google Scholar 

  9. King AB, Goldman HB. Bladder outlet obstruction in women: functional causes. Curr Urol Rep. 2014;15(9):436.

    Article  PubMed  Google Scholar 

  10. Jiang YH, Liao CH, Kuo HC. Current and potential urological applications of botulinum toxin a. Nat Rev Urol. 2015;12(9):519–33.

    CAS  Article  PubMed  Google Scholar 

  11. Kim DK, Lee JY, Jung JH, Kim JH, Hah YS, Hong CH, et al. Alpha-1 adrenergic receptor blockers for the treatment of lower urinary tract symptoms in women: a systematic review and meta-analysis. Int Neurourol J. 2019;23(1):56–68.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Chen YC, Kuo HC. Clinical and video urodynamic characteristics of adult women with dysfunctional voiding. J Formosan Med Assoc = Taiwan yi zhi. 2014;113(3):161–5.

    Article  PubMed  Google Scholar 

  13. Morin F, Akhavizadegan H, Kavanagh A, Moore K. Dysfunctional voiding: challenges of disease transition from childhood to adulthood. Can Urol Assoc J = Journal de l'Association des urologues du Canada. 2018;12(4 Suppl 1):S42–7.

    Article  PubMed  Google Scholar 

  14. Jiang YH, Wang CC, Kuo HC. OnabotulinumtoxinA urethral sphincter injection as treatment for non-neurogenic voiding dysfunction—a randomized, double-blind, placebo-controlled study. Sci Rep. 2016;6:38905.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. Lemack GE, Zimmern PE. Pressure flow analysis may aid in identifying women with outflow obstruction. J Urol. 2000;163(6):1823–8.

    CAS  Article  Google Scholar 

  16. Haylen BT, Ashby D, Sutherst JR, Frazer MI, West CR. Maximum and average urine flow rates in normal male and female populations—the Liverpool nomograms. Br J Urol. 1989;64(1):30–8.

    CAS  Article  PubMed  Google Scholar 

  17. Groutz A, Blaivas JG. Non-neurogenic female voiding dysfunction. Curr Opin Urol. 2002;12(4):311–6.

    Article  Google Scholar 

  18. Peng CH, Chen SF, Kuo HC. Videourodynamic analysis of the urethral sphincter overactivity and the poor relaxing pelvic floor muscles in women with voiding dysfunction. Neurourol Urodyn. 2017;36(8):2169–75.

    Article  PubMed  Google Scholar 

  19. Wada N, Kita M, Hashizume K, Matsumoto S, Kakizaki H. Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow study. Neurourol Urodyn. 2013;32(8):1123–7.

    CAS  Article  PubMed  Google Scholar 

  20. Rigatti L, Naspro R, Salonia A, Centemero A, Ghezzi M, Guazzoni G, et al. Urodynamics after TURP and HoLEP in urodynamically obstructed patients: are there any differences at 1 year of follow-up? Urology. 2006;67(6):1193–8.

    Article  PubMed  Google Scholar 

  21. Gravina GL, Costa AM, Ronchi P, Galatioto GP, Luana G, Vicentini C. Bladder outlet obstruction index and maximal flow rate during urodynamic study as powerful predictors for the detection of urodynamic obstruction in women. Neurourol Urodyn. 2007;26(2):247–53.

    Article  PubMed  Google Scholar 

  22. Pummangura N, Kochakarn W. Efficacy of tamsulosin in the treatment of lower urinary tract symptoms (LUTS) in women. Asian J Surg. 2007;30(2):131–7.

    Article  PubMed  Google Scholar 

  23. Kim SO, Hwang EC, Oh KJ, Kwon D, Park K, Ryu SB. Efficacy and safety of combined therapy with tamsulosin and tolterodine in female patients with a maximal flow rate less than 12 ml/s. Int Urogynecol J. 2011;22(10):1287–91.

    Article  PubMed  Google Scholar 

  24. Pischedda A, Pirozzi Farina F, Madonia M, Cimino S, Morgia G. Use of alpha1-blockers in female functional bladder neck obstruction. Urol Int. 2005;74(3):256–61.

    CAS  Article  PubMed  Google Scholar 

  25. Low BY, Liong ML, Yuen KH, Chee C, Leong WS, Chong WL, et al. Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial. J Urol. 2008;179(4):1461–9.

    CAS  Article  PubMed  Google Scholar 

  26. Lee YS, Lee KS, Choo MS, Kim JC, Lee JG, Seo JT, et al. Efficacy of an alpha-blocker for the treatment of nonneurogenic voiding dysfunction in women: an 8-week, randomized, double-blind, placebo-controlled trial. Int Neurourol J. 2018;22(1):30–40.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Xu D, Qu C, Meng H, Ren J, Zhu Y, Min Z, et al. Dysfunctional voiding confirmed by transdermal perineal electromyography, and its effective treatment with baclofen in women with lower urinary tract symptoms: a randomized double-blind placebo-controlled crossover trial. BJU Int. 2007;100(3):588–92.

    CAS  Article  PubMed  Google Scholar 

  28. Chen CH, Hsiao SM, Chang TC, Wu WY, Lin HH. Clinical and urodynamic effects of baclofen in women with functional bladder outlet obstruction: preliminary report. J Obstet Gynaecol Res. 2016;42(5):560–5.

    CAS  Article  PubMed  Google Scholar 

  29. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum a toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139(5):919–22.

    CAS  Article  PubMed  Google Scholar 

  30. Steinhardt GF, Naseer S, Cruz OA. Botulinum toxin: novel treatment for dramatic urethral dilatation associated with dysfunctional voiding. J Urol. 1997;158(1):190–1.

    CAS  Article  PubMed  Google Scholar 

  31. Phelan MW, Franks M, Somogyi GT, Yokoyama T, Fraser MO, Lavelle JP, et al. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol. 2001;165(4):1107–10.

    CAS  Article  Google Scholar 

  32. Kuo HC. Botulinum a toxin urethral injection for the treatment of lower urinary tract dysfunction. J Urol. 2003;170(5):1908–12.

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations



PM Chow: Manuscript writing, Data management, Data analysis.

SM Hsiao: Data analysis.

HC Kuo: Project development.

Corresponding author

Correspondence to Hann-Chorng Kuo.

Ethics declarations

Conflict of interest


Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material


(DOCX 16 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chow, PM., Hsiao, SM. & Kuo, HC. Obstructive patterns in videourodynamic studies predict responses of female dysfunctional voiding treated with or without urethral botulinum toxin injection: a long-term follow-up study. Int Urogynecol J 31, 2557–2564 (2020).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • Videourodynamics
  • Dysfunctional voiding
  • Botulinum toxin